Danielle B.
- Country
- France
- Department
- médecine nucléaire
Research Overview
- Phase III Multicenter Trial Comparing Systematic Versus Serum Tg and RAI Scintigraphy-Guided Radioiodine Therapy in Intermediate-Risk Differentiated Thyroid Cancer
- Evaluation of Retreatment Protocols with Lutetium (177Lu) Oxodotreotide in Patients with Progressive Intestinal Well-Differentiated Neuroendocrine Tumors
Data & Insights
Has run more than one trial at 16 of 34 partner sites.
Specializations
Thyroid Cancer Management
The investigator specializes in the treatment of differentiated thyroid cancer, with particular emphasis on optimizing radioiodine therapy approaches for intermediate-risk patients.
- Risk-stratified treatment protocols
- Post-operative assessment strategies
- Serum thyroglobulin monitoring
Their work extends to evaluating personalized treatment decision-making based on diagnostic markers.
Advanced Thyroid Cancer Treatment
Focus on treating radioiodine-refractory thyroid carcinoma with bone metastases through innovative therapeutic combinations including lenvatinib and denosumab.
- Bone metastasis management
- Targeted therapy approaches
- Multi-modal treatment strategies
Their expertise includes managing complex cases of metastatic thyroid disease.
Neuroendocrine Tumor Research
Investigation of advanced treatment protocols for well-differentiated neuroendocrine tumors, particularly focusing on Lutathera® therapy optimization.
- Treatment sequencing strategies
- Therapy resistance management
- Progressive disease interventions
Their research explores innovative retreatment approaches for progressive neuroendocrine tumors.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.